Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-08-16
|
LN-145 |
cervical cancer |
2 |
Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) |
Cancer - Oncology |
2017-08-15
|
Opdivo® (nivolumab)+Yervoy® (ipilimumab) |
previously untreated advanced or metastatic renal cell carcinoma |
3 |
BMS (USA - NY) |
Cancer - Oncology |
2017-08-14
|
Qapzola™ (apaziquone) |
non-muscle invasive bladder cancer |
3 |
Spectrum Pharmaceuticals (USA - NV) |
Cancer - Oncology |
2017-08-14
|
emricasan |
NASH (non-alcoholic steatohepatitis) |
2b |
Conatus Pharmaceuticals (USA - CA) |
Hepatic diseases - Liver diseases |
2017-08-14
|
ZYN002 CBD gel |
knee pain due to osteoarthritis |
2 |
Zynerba Pharmaceuticals (USA - PA) |
Rheumatic diseases - Inflammatory diseases |
2017-08-11
|
fimaChem technology |
inoperable extrahepatic bile duct cancer |
1 |
PCI Biotech (Norway) |
Cancer - Oncology |
2017-08-10
|
anti-Claudin18.2-CAR-T cell therapy |
gastric cancer, pancreatic cancer |
1 |
CARsgen Therapeutics (China) |
Cancer - Oncology |
2017-08-10
|
Diamyd® |
type 1 diabetes |
|
Diamyd Medical (Sweden) |
Autoimmune diseases - Metabolic diseases |
2017-08-09
|
Aplidin® (plitidepsin) in combination with pomalidomide, bortezomib and dexamethasone |
multiple myeloma |
|
PharmaMar (Spain) |
Cancer - Oncology |
2017-08-08
|
KITE-585 |
relapsed/refractory multiple myeloma |
1 |
Kite Pharma (USA - CA) |
Cancer - Oncology |
2017-08-08
|
RXI-762 and RXI-804 |
|
preclinical |
RXi Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2017-08-08
|
RGX-111 (adeno-associated virus vector serotype 9 expressing human a-L-iduronidase) |
mucopolysaccharidosis type I |
1 |
RegenXBio (USA - MD) |
Rare diseases - Genetic diseases |
2017-08-07
|
gemcabene |
patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy, including patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD), who have baseline LDL-C (“bad cholesterol”) values ? 100 mg/dL |
2b |
Gemphire Therapeutics (USA - Mich) |
Rare diseases - Genetic diseases - Cardiovascular diseases |
2017-08-07
|
TPIV 200 (multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant) |
platinum sensitive ovarian cancer |
2 |
Tapimmune (USA - FL) |
Cancer - Oncology |
2017-08-03
|
|
refractory aggressive non-Hodgkin lymphoma (NHL) |
|
|
Cancer - Oncology |
2017-08-02
|
|
major depressive disorder, bipolar depression |
|
23andMe (USA - CA) Lundbeck (Denmark) Milken Institute (USA - CA) |
CNS diseases - Mental diseases |
2017-08-02
|
omecamtiv mecarbil |
heart failure |
2 |
Cytokinetics (USA - CA) |
Cardiovascular diseases |
2017-08-02
|
pracinostat |
acute myeloid leukemia (AML) |
3 |
Mei Pharma (USA - CA) Helsinn Group (Switzerland) |
Cancer - Oncology |
2017-08-02
|
axicabtagene ciloleucel (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) |
relapsed/refractory indolent B-cell non-Hodgkin lymphoma |
2 |
Kite Pharma (USA - CA) |
Cancer - Oncology |
2017-08-02
|
Pixuvri® (pixantrone) |
relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma |
3 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) |
Cancer - Oncology |